Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, Mass.–(BUSINESS WIRE)–$AVRO—AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has granted…
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), has completed patient enrollment in its Phase 2 clinical trial of AR-1105 in…
PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter…
Expanded indication allows for treatment of women whose advanced ovarian cancer is associated with homologous recombination deficiency (HRD) Zejula is…
ICON has acquired Symphony Clinical Research, to boost its ability to offer customers hybrid trial solutions and site support services,…
Dr.Reddy’s has started a recall in USA of its ranitidine, to confirmed contamination with N-Nitrosodimethylamine (NDMA), classified as a probable…
Janssen has submitted a type II variation application to European Medicines agency, looking to get approved guselkumab, which could then…
Alexion finished the third quarter 2019 with total revenues of $1,263.1 million, which represents a 23% increase over 3the same…
The CoFI™ System is indicated for diagnostic assessment of the coronary microcirculation immediately following PCI (“stenting”), and to be a…
Hemogenyx Pharmaceuticals has signed a research agreement through is subsidiary Immugenyx, to develop humanized mice as a tool for drug development and testing, including with a global pharmaceutical company, whose identity must remain hidden at its request.